Wan Yu Png1, Yu Heng Kwan2, Ka Keat Lim2, Eng Hui Chew1, Nai Lee Lui3, Chuen Seng Tan4, Truls Østbye2, Julian Thumboo2,3, Warren Fong3,5,6. 1. Department of Pharmacy, National University of Singapore, Singapore. 2. Program in Health Services and Systems Research, Duke-NUS Medical School, Singapore. 3. Department of Rheumatology and Immunology, Singapore General Hospital, Singapore. 4. Saw Swee Hock School of Public Health, National University of Singapore, Singapore. 5. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. 6. Duke-NUS Medical School, Singapore.
Abstract
OBJECTIVES: Biologicals play a crucial role in managing some of the rheumatological diseases, thus it is important for clinicians, healthcare institutions and policy-makers to understand why biologicals are initiated or refused so as to make better decisions to improve patients' disease outcomes. Although there have been many studies investigating factors associated with the initiation of biologicals for patients with rheumatological conditions, there have been no systematic reviews that provide a comprehensive summary. We aim to provide a summary of factors associated with biologicals' initiation for patients with rheumatological conditions. METHODS: We performed a literature search in PubMed, Embase and PsycINFO. We identified and screened studies according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Factors were presented according to patient, disease-related, therapy-related, healthcare team-related and system in-place factors. RESULTS: A total 1755 articles were reviewed and 24 articles were found to be relevant to our objective. Forty four factors reviewed were placed into five main categories: patient factors (n=13); disease-related factors (n=11); therapy-related factors (n=7); healthcare team-related factors (n=4) and system in-place-related factors (n=9). The factors studied by the published papers found to be associated with decisions to initiate biologicals varied widely. CONCLUSION: Forty two factors of five different categories were found to be associated with biologicals' initiation for patients with rheumatological conditions. Clinicians need to be mindful of the complex nature of these factors to optimise therapy of patients with rheumatological conditions. Healthcare institutions and policy- makers ought to be aware of any potential barriers to successful biologicals' treatment and address them accordingly.
OBJECTIVES: Biologicals play a crucial role in managing some of the rheumatological diseases, thus it is important for clinicians, healthcare institutions and policy-makers to understand why biologicals are initiated or refused so as to make better decisions to improve patients' disease outcomes. Although there have been many studies investigating factors associated with the initiation of biologicals for patients with rheumatological conditions, there have been no systematic reviews that provide a comprehensive summary. We aim to provide a summary of factors associated with biologicals' initiation for patients with rheumatological conditions. METHODS: We performed a literature search in PubMed, Embase and PsycINFO. We identified and screened studies according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Factors were presented according to patient, disease-related, therapy-related, healthcare team-related and system in-place factors. RESULTS: A total 1755 articles were reviewed and 24 articles were found to be relevant to our objective. Forty four factors reviewed were placed into five main categories: patient factors (n=13); disease-related factors (n=11); therapy-related factors (n=7); healthcare team-related factors (n=4) and system in-place-related factors (n=9). The factors studied by the published papers found to be associated with decisions to initiate biologicals varied widely. CONCLUSION: Forty two factors of five different categories were found to be associated with biologicals' initiation for patients with rheumatological conditions. Clinicians need to be mindful of the complex nature of these factors to optimise therapy of patients with rheumatological conditions. Healthcare institutions and policy- makers ought to be aware of any potential barriers to successful biologicals' treatment and address them accordingly.
Entities:
Keywords:
clinical pharmacy; rheumatology; social medicine
Authors: Bert Vander Cruyssen; Clio Ribbens; Annelies Boonen; Herman Mielants; Kurt de Vlam; Jan Lenaerts; Serge Steinfeld; Filip Van den Bosch; Lode Dewulf; Nathan Vastesaeger Journal: Ann Rheum Dis Date: 2007-01-29 Impact factor: 19.103
Authors: T Pham; R Landewé; S van der Linden; M Dougados; J Sieper; J Braun; J Davis; M Rudwaleit; E Collantes; R Burgos-Vargas; J Edmonds; I Olivieri; I van der Horst-Bruinsma; H Mielants; M Stone; P Emery; D van der Heijde Journal: Ann Rheum Dis Date: 2006-02-07 Impact factor: 19.103
Authors: Elisabeth J M Zirkzee; Arina C Sneep; Petronella D M de Buck; Cornelia F Allaart; Andreas J Peeters; H Karel Ronday; Marie Louise Westedt; Saskia le Cessie; Theodora P M Vliet Vlieland Journal: Clin Rheumatol Date: 2007-05-10 Impact factor: 2.980
Authors: M Elaine Husni; Eunice Chang; Michael S Broder; Caleb Paydar; Katalin Bognar; Pooja Desai; Yuri Klyachkin; Ibrahim Khilfeh Journal: Open Access Rheumatol Date: 2022-06-15